![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Fagron NV | EU:FAGR | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.04 | 0.21% | 18.66 | 18.44 | 18.80 | 18.66 | 18.44 | 18.62 | 31,906 | 16:40:00 |
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 October 2022 – 7.00 AM CET
Fagron delivers topline growth of 21.5% to €173 million
Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2022.
Key Highlights
Rafael Padilla, CEO of Fagron comments
“Our results in the third quarter demonstrate the resilience in our business with positive developments in several markets despite an increasingly challenging macro environment. The performance in EMEA has continued its upwards trajectory following a series of actions aimed at enhancing our competitive edge as well as driving efficiencies. In Latin America, increased competitive pressure and end market softness endure and we remain focused on maintaining market leadership by further optimizing operations and driving commercial efficacy to protect profitability. Finally, in North America, we have further reinforced our focus on quality but have seen impact from various external factors such as a continuation of the syringe shortages and shipment disruptions due to Hurricane Ian.
Given the syringe shortages are likely to linger, we expect our Wichita run rate to remain at current levels through the fourth quarter, despite strong underlying demand, and achieve at least US$95m (annualized) at the end of the period. Combining this with the recently acquired 503B outsourcing facility in Boston, where we have made strong progress by utilizing our commercial expertise at Wichita and have onboarded several new clients, we expect the joint run rate by the end of the year to be above US$110m (annualized).
We remain confident about the prospects of our business globally and reiterate our FY 2022 and mid-term guidance provided earlier in the year".
Please open the link below for the full press release:Fagron delivers topline growth of 21.5% to €173 million
1 Year Fagron NV Chart |
1 Month Fagron NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions